Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 272.50
Bid: 270.00
Ask: 275.00
Change: 30.00 (12.37%)
Spread: 5.00 (1.85%)
Open: 262.50
High: 272.50
Low: 255.00
Yest. Close: 242.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Mon, 13th Jan 2020 11:54

(Alliance News) - Faron Pharmaceuticals Oy said Monday it has received approval from the MATINS trial's data monitoring committee to expand the clinical trial of its Clevegen cancer drug.

The MATINS clinical trial is investigating the drug, which targets both metastatic cancers, forms of the disease which spread to new areas of the body, and inoperable tumours, which cannot be removed from the body surgically.

Turku, Finland-based Faron said the data monitoring committee has accepted its proposal that the initial Clevegen dose for part II of the study should be 0.3 milligrams per kilogramme.

A total of ten late-stage colorectal, or bowel, cancer patients are expected to be dosed in this 0.3 milligrams per kilogram cohort, including two patients who had previously received this dose in the earlier part I of the study.

In the first part of the study, patients received Clevegen dosage amounts of 0.1 milligramme per kilogramme, 0.3 milligrams per kilogramme, 1.0 milligrams per kilogramme, 3.0 milligrams per kilogramme or 10 milligrams per kilogramme.

Faron said: "While the dose of 0.3 milligrams per kilogramme has been associated with a clinical response and has produced the strongest immune response, the efficacy of another Part I dose level cohort may be tested separately during Part II following completion and final analysis of Part I."

Faron Chief Executive Officer Markku Jalkanen said: "We continue to be impressed by the potential of Clevegen and are very pleased to have the data monitoring committee support for the commencement of part II of the MATINS trial."

Following the approval of Clevegen as an investigational new drug by the US Food & Drug Administration in November, the company said it is opening new MATINS trials in the US to facilitate its "rapid expansion" beyond existing new sites in Europe.

Faron Pharma shares were trading 4.2% higher in London at 284.00 pence each on Monday.

By Loreta Juodagalvyte; loretajuodagalvyte@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

6 Feb 20 14:17

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

27 Jan 20 11:22

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

13 Jan 20 11:54

Faron Pharma requests arbitration over Traumakine manufacturing deal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.

30 Dec 19 15:39

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

30 Dec 19 10:56

Faron Pharmaceuticals upbeat on new data from 'MATINS' study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.

11 Dec 19 13:42

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

11 Dec 19 10:45

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

29 Nov 19 10:23

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

28 Nov 19 11:56

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

21 Nov 19 12:56

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

8 Nov 19 10:30

Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress

Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress

7 Nov 19 17:59

LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week

LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week

1 Nov 19 16:58

Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge

Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge

1 Nov 19 15:32

Faron Pharmaceuticals positive on feedback from 'Clevegen' monitoring committee

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced feedback from the 'MATINS' study data monitoring committee on Wednesday, from the ongoing dose escalation study from part 1 of the MATINS trial.

9 Oct 19 14:05

Login to your account

Don't have an account? Click here to register.